Antibody-drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), ...

Now is a great time for income and value investors, especially in energy and pharma, with dividends and upside potential.

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

India's Department of Pharmaceuticals found AbbVie Healthcare India sponsored ₹1.91 crore in international trips for 30 ...

FQAL offers a stable, high-quality portfolio with strong fundamentals but has lagged peers in returns, favoring investors.

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.